2.4. Adoptive immunotherapy with T lymphocytes from HIFU-treated mice

Sixty syngeneic H₂₂ tumor mice were used for assessment of the adoptive immunotherapy. They were divided into three groups (HIFU, sham-HIFU and control) and each group had 20 mice. They received the adoptive transfer of the T cell suspensions obtained from the HIFU, sham-HIFU and naïve mice respectively. In brief, a total of 1 × 10⁶ T cells (2 × 10⁷/mL, 0.05 mL) were intravenously injected each time via a tail vein for each mouse, and this adoptive cell transfer was carried out twice on day 3 and 4 after H₂₂ tumor implantation. All mice in each group received the same quality and quantity of T-cell suspension from HIFU-treated mice.